Ascendis Pharma A/S (ASND:NASDAQ) closed at $245.15 on October 26, 2026, up 0.73% on the day. The stock trades 13.1% below its 52-week high of $282.15 and 30.3% above its 52-week low of $188.07. Over the past year, it gained 20.6%. Ascendis Pharma A/S is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 24, 2025, ASND closed higher on 124 days (49%). Its best day was June 25, 2026 (+9.90%) and its worst was September 15, 2026 (-9.49%). It never moved 10% or more in a single session.
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; and TransCon Treprostinil that is in Phase I clinical trial for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Peptides for the treatment of diabetes; TransCon ranibizumab, a compound to support injection of ranibizumab in ophthalmology; TransCon parathyroid hormone for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It has strategic collaborations with Sanofi and Genentech. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark.
Find more stocks like ASND with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.